The Mucosal and Vaccine Research Colorado (MAVRC) program is soliciting applications for pilot grant funding for collaborative human immunobiology studies. MAVRC promotes new interactions between a diverse spectrum of researchers to explore mucosal and vaccine biology and disease. Our goal is to foster and facilitate the development of innovative collaborative, interdisciplinary biomedical research programs in human mucosal biology, immunology and vaccine development.

Eligibility
Applicant teams will include basic and clinical faculty investigators, with an emphasis on new interdepartmental or inter-institutional collaborations. Proposals will represent new and creative projects investigating human immunobiology, supported by a concrete plan for specific subsequent external funding. Submissions will be reviewed by the MAVRC Board of Directors for significance, innovation, approach, and budget. Relevant IRB approval must be attained prior to the grant allocation.

Two innovative pilot projects will be selected to receive a $25,000 grant for studies to be conducted within a one year period, with no carryover. The grants will cover direct costs only, including supplies, (non Principal Investigator) salaries, patient costs, and should not supplement other grants.

Applications
Applications are due September 1st in pdf form emailed to MAVRC@ucdenver.edu. A three-page proposal (covering numbers 2-6; Arial 11 font) in NIH format will include:
1. Cover page (Title and Investigators)
2. Hypotheses
3. Specific Objectives
4. Background, including special significance
5. Work proposed
6. Plan for subsequent funding
7. IRB plan for protection of human subjects (approval due prior to funding)
8. Budget (direct costs only; no indirect costs provided) (one page)
9. NIH biosketch of each Investigator

Notification of Awards
Selected awardees will be announced October 1st. Brief summary statements will be provided. Funding commences with IRB approval.